Skye Bioscience, Inc. (SKYE)
0.9901
-0.05
(-4.80%)
USD |
NASDAQ |
Nov 06, 10:25
Skye Bioscience Enterprise Value : -5.317M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -5.317M |
| November 04, 2026 | -4.877M |
| November 03, 2026 | -4.526M |
| November 02, 2026 | -4.087M |
| October 30, 2026 | -4.262M |
| October 29, 2026 | -4.131M |
| October 28, 2026 | -3.208M |
| October 27, 2026 | -3.516M |
| October 26, 2026 | -2.988M |
| October 23, 2026 | -3.120M |
| October 22, 2026 | -2.769M |
| October 21, 2026 | -2.725M |
| October 20, 2026 | -2.769M |
| October 19, 2026 | -3.164M |
| October 16, 2026 | -3.076M |
| October 15, 2026 | -2.900M |
| October 14, 2026 | -2.988M |
| October 13, 2026 | -3.164M |
| October 12, 2026 | -2.944M |
| October 09, 2026 | -2.461M |
| October 08, 2026 | -2.505M |
| October 07, 2026 | -2.637M |
| October 06, 2026 | -2.769M |
| October 05, 2026 | -2.286M |
| October 02, 2026 | -2.505M |
| Date | Value |
|---|---|
| October 01, 2026 | -2.857M |
| September 30, 2026 | -2.813M |
| September 29, 2026 | -2.900M |
| September 28, 2026 | -2.813M |
| September 25, 2026 | -2.549M |
| September 24, 2026 | -2.417M |
| September 23, 2026 | -1.978M |
| September 22, 2026 | -2.373M |
| September 21, 2026 | -2.066M |
| September 18, 2026 | -2.132M |
| September 17, 2026 | -2.988M |
| September 16, 2026 | -2.417M |
| September 15, 2026 | -0.6162M |
| September 14, 2026 | -1.143M |
| September 11, 2026 | -0.9237M |
| September 10, 2026 | -0.748M |
| September 09, 2026 | -0.089M |
| September 08, 2026 | -1.627M |
| September 04, 2026 | -1.714M |
| September 03, 2026 | -2.066M |
| September 02, 2026 | -1.802M |
| September 01, 2026 | -1.978M |
| August 31, 2026 | -2.505M |
| August 28, 2026 | -2.088M |
| August 27, 2026 | -1.319M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.79M |
| Total Expenses (Quarterly) | 10.79M |
| EPS Diluted (Quarterly) | -2.174 |
| Earnings Yield | -1.03K% |
| Normalized Earnings Yield | -981.92 |